Cover Image
市場調查報告書

乾眼症症候群:歐洲主要5個國家 (EU5)的醫藥品市場預測與分析

Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024

出版商 GlobalData 商品編碼 366914
出版日期 內容資訊 英文 197 Pages
訂單完成後即時交付
價格
Back to Top
乾眼症症候群:歐洲主要5個國家 (EU5)的醫藥品市場預測與分析 Dry Eye Syndrome - 5EU Drug Forecast and Market Analysis to 2024
出版日期: 2015年11月05日 內容資訊: 英文 197 Pages
簡介

歐洲主要5個國家的乾眼症症候群的治療藥的市場規模,2014年時刻達到了1億8100萬美元。參天製藥在2015年Ikervis上市,推動今後的市場成長。其他各種治療藥今後開發、上市的結果,到2024年的年複合成長率 (CAGR) 預計達到36.9%。

本報告提供歐洲的主要5個國家 (法國、德國、義大利、西班牙、英國) 的乾眼症症候群 (DES) 治療藥臨床實驗趨勢與上市預測相關分析,DES概要 (病因、病理、症狀、診斷方法等) ,及目前的主要治療方法,現在臨床實驗中/已上市的開發中產品的概要 (功效,SWOT分析等),市場規模預測 (今後11年份),主要的推動市場要素與其影響度等相關的調查評估。

第1章 目錄

第2章 簡介

  • 相關報告

第3章 疾病概要

  • 病因與病情
    • 病因
    • 病理生理學
  • 疾病的分類
  • 症狀
  • 預後
  • 生活品質 (QoL)

第4章 疾病管理

  • 診斷、治療方法概要
    • 診斷
    • 治療指南
    • 臨床診療
  • (EU5歐洲主要5個國家)

第5章 競爭力的評估

  • 概要
  • 產品簡介
    • Restasis (Cyclosporine)
    • Diquas (diquafosol tetrasodium)
    • Mucosta點眼藥液 (rebamipide)
    • Ikervis (Cyclosporine)
    • 人工淚液
    • 其他的治療藥物

第6章 未滿足需求與市場機會

  • 概要
  • 乾眼症症候群 (DES)的新治療方法
    • 未滿足需求
    • 差距分析
    • 市場機會
  • 診斷工具的改良
  • 遵照法規的確實認證的,恰當的臨床實驗設計
  • 投藥法的簡單化
  • 患者的抗性、遵守改善的教育
  • 改善醫生、患者對疾病相關的認識

第7章 開發中產品的評估

  • 概要
  • 臨床實驗製圖
    • 乾眼症症候群 (DES)的臨床實驗設計
    • Ora的DES治療藥開發的動向
  • 臨床實驗階段有潛力的醫藥品
    • Lifitegrast
    • Tavilermide
    • Visomitin
    • RGN-259
    • Cis-UCA
    • SI-614
  • 臨床實驗的初期階段有潛力的醫藥品
    • KPI-121
    • Ozagrel
    • P-321
    • Dextenza (OTX-DP)
  • 臨床實驗中的其他的醫藥品

第8章 市場未來展望

  • 歐洲主要5個國家
    • 預測
    • 近幾年主要的事件
    • 市場促進、阻礙因素

第9章 附錄

圖表一覽

目錄
Product Code: GDHC300CFR

Dry Eye Syndrome (DES), also known as keratoconjunctivitis sicca, is a multifactorial disease of the tears and ocular surface. This ocular condition can cause ocular discomfort, visual disturbances, and tear film instability, which can potentially damage the ocular surface. The DES market has had few new therapeutics in the last decade with Japan seeing the most change in this time with the arrival of Diquas and Mucosta in 2010 and 2013, respectively. However, the lack of treatment options is about to change with the expected launch of numerous pipeline DES drugs during the forecast period, which will be a significant driver of growth in the 9MM. Indeed, this change has already been initiated with Ikervis' recent arrival in Europe in 2015. Furthermore, additional marketing approvals are being sought for currently marketed DES drugs, Restasis and Diquas, in new countries in the 9MM, which will provide a source of growth in this market.

GlobalData estimated that DES drug sales in the 5EU reached $181m during the base year of 2014. The launch of Santen's new DES drug, Ikervis, in 2015 will be the main driver for this significant growth in these markets. The expected arrival of pharmacotherapies into the DES market in the 5EU during the forecast period will cause the relative market share of these artificial tears products to drastically fall to 36.9% by 2024.

Scope

  • Overview of DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on the key drugs in 5EU including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for the top drugs in 5EU from 2014-2024.
  • Analysis of the impact of key events as well the drivers and restraints affecting 5EU DES market.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for DES.
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of drug performance
  • Obtain sales forecast for drugs from 2014-2024 in 5EU.

Table of Contents

1. Table of Contents

  • 1.1. List of Tables
  • 1.2. List of Figures

2. Introduction

  • 2.1. Related Reports

3. Disease Overview

  • 3.1. Etiology and Pathophysiology
    • 3.1.1. Etiology
    • 3.1.2. Pathophysiology
  • 3.2. Disease Classification
  • 3.3. Symptoms
  • 3.4. Prognosis
  • 3.5. Quality of Life

4. Disease Management

  • 4.1. Diagnosis and Treatment Overview
    • 4.1.1. Diagnosis
    • 4.1.2. Treatment Guidelines
    • 4.1.3. Clinical Practice
  • 4.2. 5EU

5. Competitive Assessment

  • 5.1. Overview
  • 5.2. Product Profiles
    • 5.2.1. Restasis (cyclosporine)
    • 5.2.2. Diquas (diquafosol tetrasodium)
    • 5.2.3. Mucosta ophthalmic solution (rebamipide)
    • 5.2.4. Ikervis (cyclosporine)
    • 5.2.5. Artificial Tears
    • 5.2.6. Other therapies

6. Unmet Need and Opportunity

  • 6.1. Overview
  • 6.2. New Therapies for DES
    • 6.2.1. Unmet Need
    • 6.2.2. Gap Analysis
    • 6.2.3. Opportunity
  • 6.3. Better Diagnostic Tools
    • 6.3.1. Unmet Need
    • 6.3.2. Gap Analysis
    • 6.3.3. Opportunity
  • 6.4. Appropriate Clinical Trial Design to Secure Regulatory Approval
    • 6.4.1. Unmet Need
    • 6.4.2. Gap Analysis
    • 6.4.3. Opportunity
  • 6.5. Simplified Dosing
    • 6.5.1. Unmet Need
    • 6.5.2. Gap Analysis
    • 6.5.3. Opportunity
  • 6.6. Patient Education to Improve Tolerance and Compliance
    • 6.6.1. Unmet Need
    • 6.6.2. Gap Analysis
    • 6.6.3. Opportunity
  • 6.7. Improved Physician and Patient Disease Awareness
    • 6.7.1. Unmet Need
    • 6.7.2. Gap Analysis
    • 6.7.3. Opportunity

7. Pipeline Assessment

  • 7.1. Overview
  • 7.2. Clinical Trial Mapping
    • 7.2.1. Clinical Trial Design for DES
    • 7.2.2. Ora for DES Drug Development
  • 7.3. Promising Drugs in Clinical Development
    • 7.3.1. Lifitegrast
    • 7.3.2. Tavilermide
    • 7.3.3. Visomitin
    • 7.3.4. RGN-259
    • 7.3.5. Cis-UCA
    • 7.3.6. SI-614
  • 7.4. Promising Drugs in Early-Stage Development
    • 7.4.1. KPI-121
    • 7.4.2. Ozagrel
    • 7.4.3. P-321
    • 7.4.4. Dextenza (OTX-DP)
  • 7.5. Other Drugs in Development

8. Market Outlook

  • 8.1. 5EU
    • 8.1.1. Forecast
    • 8.1.2. Key Events
    • 8.1.3. Drivers and Barriers

9. Appendix

  • 9.1. Bibliography
  • 9.2. Abbreviations
  • 9.3. Methodology
  • 9.4. Forecasting Methodology
    • 9.4.1. Diagnosed DES Patients
    • 9.4.2. Percent Drug-Treated Patients
    • 9.4.3. Launch Dates
    • 9.4.4. General Pricing Assumptions
    • 9.4.5. Individual Drug Assumptions
    • 9.4.6. Pricing of Pipeline Agents
  • 9.5. Primary Research - KOLs Interviewed for this Report
  • 9.6. Primary Research - High-prescriber Survey
  • 9.7. About the Authors
    • 9.7.1. Analyst
    • 9.7.2. Therapy Area Director
    • 9.7.3. Epidemiologist
    • 9.7.4. Global Head of Healthcare
  • 9.8. About GlobalData
  • 9.9. Disclaimer

List of Tables

  • Table 1: Symptoms of Dry Eye Syndrome
  • Table 2: National and International Treatment Guidelines for DES
  • Table 3: Country Profile - 5EU
  • Table 4: Leading Treatments for DES, 2015
  • Table 5: Product Profile - Restasis
  • Table 6: Restasis SWOT Analysis, 2015
  • Table 7: Global Sales Forecast ($m) for Restasis, 2014-2024
  • Table 8: Product Profile - Diquas
  • Table 9: Diquas SWOT Analysis, 2015
  • Table 10: Global Sales Forecast ($m) for Diquas, 2014-2024
  • Table 11: Product Profile - Mucosta
  • Table 12: Mucosta SWOT Analysis, 2015
  • Table 13: Global Sales Forecast ($m) for Mucosta, 2014-2024
  • Table 14: Product Profile - Ikervis
  • Table 15: Ikervis SWOT Analysis, 2015
  • Table 16: Global Sales Forecast ($m) for Ikervis, 2014-2024
  • Table 17: Artificial Tears SWOT Analysis, 2015
  • Table 18: Global Sales Forecast ($m) for Artificial Tears, 2014-2024
  • Table 19: Unmet Needs and Opportunities in DES
  • Table 20: Promising Drugs in Clinical Development for Dry Eye Syndrome, 2015
  • Table 21: Comparison of Drugs in Development for Dry Eye Syndrome, 2015
  • Table 22: Product Profile - Lifitegrast
  • Table 23: SWOT Analysis - Lifitegrast, 2015
  • Table 24: Global Sales Forecast ($m) for Lifitegrast, 2014-2024
  • Table 25: Product Profile - Tavilermide
  • Table 26: SWOT Analysis - tavilermide, 2015
  • Table 27: Global Sales Forecast ($m) for tavilermide, 2014-2024
  • Table 28: Product Profile - Visomitin
  • Table 29: SWOT Analysis - Visomitin, 2015
  • Table 30: Global Sales Forecast ($m) for Visomitin, 2014-2024
  • Table 31: Product Profile - RGN-259
  • Table 32: SWOT Analysis - RGN-259, 2015
  • Table 33: Global Sales Forecast ($m) for RGN-259, 2014-2024
  • Table 34: Product Profile - Cis-UCA
  • Table 35: Product Profile - SI-614
  • Table 36: Drugs in Development, 2015
  • Table 37: 5EU Sales Forecast ($m) for DES Therapies, 2014-2024
  • Table 38: Key Events Impacting Sales for DES Therapies in the 5EU, 2014-2024
  • Table 39: DES Market - Drivers and Barriers in the 5EU, 2014-2024
  • Table 40: National Healthcare Authorities and Governmental Drug Pricing Authorities in the 5EU Nations
  • Table 41: Key Launch Dates
  • Table 42: Surveyed High-prescribing Physicians, by Country

List of Figures

  • Figure 1: Dry Eye Syndrome - Disease Etiology
  • Figure 2: The Tear Film in normal and dry eye
  • Figure 3: Varied Symptoms of Dry Eye Syndrome
  • Figure 4: Dry Eye Syndrome Therapeutics - Phase II and II/III Clinical Trials in the 9MM, 2015
  • Figure 5: DES Phase II/Phase III Pipeline, 2015
  • Figure 6: Competitive Assessment of Late-Stage Pipeline Agents in DES, 2014-2024
  • Figure 7: Clinical and Commercial Positioning of lifitegrast
  • Figure 8: Clinical and Commercial Positioning of tavilermide
  • Figure 9: Clinical and Commercial Positioning of Visomitin
  • Figure 10: Clinical and Commercial Positioning of RGN-259
  • Figure 11: Drug Sales for DES Therapies in the 5EU, 2014 and 2024
  • Figure 12: Drug Sales by country for DES in the 5EU, 2014 and 2024
Back to Top